180 related articles for article (PubMed ID: 28292940)
1. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
[TBL] [Abstract][Full Text] [Related]
2. Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
Floc'h N; Ashton S; Ferguson D; Taylor P; Carnevalli LS; Hughes AM; Harris E; Hattersley M; Wen S; Curtis NJ; Pilling JE; Young LA; Maratea K; Pease EJ; Barry ST
Mol Cancer Ther; 2019 May; 18(5):909-919. PubMed ID: 30872381
[TBL] [Abstract][Full Text] [Related]
3. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.
Ashton S; Song YH; Nolan J; Cadogan E; Murray J; Odedra R; Foster J; Hall PA; Low S; Taylor P; Ellston R; Polanska UM; Wilson J; Howes C; Smith A; Goodwin RJ; Swales JG; Strittmatter N; Takáts Z; Nilsson A; Andren P; Trueman D; Walker M; Reimer CL; Troiano G; Parsons D; De Witt D; Ashford M; Hrkach J; Zale S; Jewsbury PJ; Barry ST
Sci Transl Med; 2016 Feb; 8(325):325ra17. PubMed ID: 26865565
[TBL] [Abstract][Full Text] [Related]
4. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
[TBL] [Abstract][Full Text] [Related]
5. Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells.
Yamauchi T; Uzui K; Shigemi H; Negoro E; Yoshida A; Ueda T
Cancer Sci; 2013 Jul; 104(7):926-33. PubMed ID: 23557198
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic polymeric nanoparticles and the methods of making and using thereof: a patent evaluation of WO2015036792.
Sarvagalla S; Hsieh HP; Coumar MS
Expert Opin Ther Pat; 2016 Jul; 26(7):751-5. PubMed ID: 27167102
[TBL] [Abstract][Full Text] [Related]
7. Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.
Payton M; Cheung HK; Ninniri MSS; Marinaccio C; Wayne WC; Hanestad K; Crispino JD; Juan G; Coxon A
Mol Cancer Ther; 2018 Dec; 17(12):2575-2585. PubMed ID: 30266802
[TBL] [Abstract][Full Text] [Related]
8. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
10. A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system.
Song YH; Shin E; Wang H; Nolan J; Low S; Parsons D; Zale S; Ashton S; Ashford M; Ali M; Thrasher D; Boylan N; Troiano G
J Control Release; 2016 May; 229():106-119. PubMed ID: 27001894
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
[TBL] [Abstract][Full Text] [Related]
12. A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.
Tsuboi K; Yokozawa T; Sakura T; Watanabe T; Fujisawa S; Yamauchi T; Uike N; Ando K; Kihara R; Tobinai K; Asou H; Hotta T; Miyawaki S
Leuk Res; 2011 Oct; 35(10):1384-9. PubMed ID: 21565405
[TBL] [Abstract][Full Text] [Related]
13. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
Walsby E; Walsh V; Pepper C; Burnett A; Mills K
Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.
Zekri A; Ghaffari SH; Yaghmaie M; Estiar MA; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
Mol Neurobiol; 2016 Apr; 53(3):1808-1823. PubMed ID: 25752998
[TBL] [Abstract][Full Text] [Related]
15. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.
Oke A; Pearce D; Wilkinson RW; Crafter C; Odedra R; Cavenagh J; Fitzgibbon J; Lister AT; Joel S; Bonnet D
Cancer Res; 2009 May; 69(10):4150-8. PubMed ID: 19366807
[TBL] [Abstract][Full Text] [Related]
16. Reactive oxygen species generation and increase in mitochondrial copy number: new insight into the potential mechanism of cytotoxicity induced by aurora kinase inhibitor, AZD1152-HQPA.
Zekri A; Mesbahi Y; Ghanizadeh-Vesali S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Anticancer Drugs; 2017 Sep; 28(8):841-851. PubMed ID: 28639950
[TBL] [Abstract][Full Text] [Related]
17. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.
Kantarjian HM; Martinelli G; Jabbour EJ; Quintás-Cardama A; Ando K; Bay JO; Wei A; Gröpper S; Papayannidis C; Owen K; Pike L; Schmitt N; Stockman PK; Giagounidis A;
Cancer; 2013 Jul; 119(14):2611-9. PubMed ID: 23605952
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.
Dennis M; Davies M; Oliver S; D'Souza R; Pike L; Stockman P
Cancer Chemother Pharmacol; 2012 Sep; 70(3):461-9. PubMed ID: 22864876
[TBL] [Abstract][Full Text] [Related]
19. AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy.
Zekri A; Ghaffari SH; Ghanizadeh-Vesali S; Yaghmaie M; Salmaninejad A; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
Tumour Biol; 2015 Feb; 36(2):623-32. PubMed ID: 25277659
[TBL] [Abstract][Full Text] [Related]
20. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]